Literature DB >> 22825521

Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review.

Marta Scorsetti1, Filippo Alongi, Elena Clerici, Pierina Navarria, Matteo Simonelli, Elisa Rognone, Armando Santoro.   

Abstract

Meningioma is a common primary brain tumor in adults. The treatment approach depends on its grade, size and symptoms. The case reported here was a repeatedly recurring transitional meningioma, previously treated with several surgical procedures and two sessions of cranial radiosurgery. At the time of last relapse, temozolomide was administered alone and combined with external beam radiation therapy. At the last follow-up after 38 months, the disease was stable. In conclusion, in this case of plurirecurrent meningioma, treatment with temozolomide alone and in combination with radiotherapy was feasible and associated with limited morbidity, providing clinical benefit and long local disease control. We discuss the case comparing our approach with other experiences reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825521     DOI: 10.1700/1125.12413

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  3 in total

1.  Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.

Authors:  Katherine Belanger; Timothy H Ung; Denise Damek; Kevin O Lillehei; D Ryan Ormond
Journal:  BMC Cancer       Date:  2022-04-07       Impact factor: 4.430

2.  Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo.

Authors:  Tao Yu; Junguo Cao; Montadar Alaa Eddine; Mahmoud Moustafa; Andreas Mock; Cihan Erkut; Amir Abdollahi; Rolf Warta; Andreas Unterberg; Christel Herold-Mende; Gerhard Jungwirth
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

3.  Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.

Authors:  Emily J Tonogai; Shan Huang; Rachel C Botham; Matthew R Berry; Stephen K Joslyn; Gregory B Daniel; Zixin Chen; Jianghong Rao; Xiang Zhang; Falguni Basuli; John H Rossmeisl; Gregory J Riggins; Amy K LeBlanc; Timothy M Fan; Paul J Hergenrother
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.